The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,807.50
Ask: 1,808.50
Change: 10.50 (0.58%)
Spread: 1.00 (0.055%)
Open: 1,797.00
High: 1,810.00
Low: 1,792.00
Prev. Close: 1,799.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK Annual Report 2023 on Form 20-F

5 Mar 2024 17:24

RNS Number : 7075F
GSK PLC
05 March 2024
 

Issued: 5 March 2024, London UK

 

GSK plc 2023 Annual Report on Form 20-F

 

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GSK plc ("GSK") announces that on 5 March 2024 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2023. GSK's 2023 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

A hard copy version of the GSK 2023 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2024.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2023, free of charge, by either:

 

(i)

writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on +44 (0)371 384 2991 (please use the area code if calling from outside the UK);

 

(ii)

writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 877 353 1154 (US toll free) or +1 651 453 2128 (outside the US); or

 

(iii)

contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

Victoria WhyteCompany Secretary5 March 2024

 

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSQKPBBOBKDKNK
Date   Source Headline
16th Jul 202112:00 pmRNSGSK announces daprodustat phase 3 headline results
16th Jul 202110:24 amRNSDirector/PDMR Shareholding
15th Jul 20211:21 pmRNSDirector/PDMR Shareholding
14th Jul 20213:34 pmRNSDirector/PDMR Shareholding
14th Jul 20213:17 pmRNSDirector/PDMR Shareholding
13th Jul 20219:44 amRNSDirector/PDMR Shareholding
13th Jul 20219:33 amRNSDirector/PDMR Shareholding
12th Jul 202110:23 amRNSDirector/PDMR Shareholding
12th Jul 202110:18 amRNSDirector/PDMR Shareholding
9th Jul 20219:30 amRNSDirector/PDMR Shareholding
2nd Jul 202112:36 pmRNSGSK and Alector collaboration in immuno-neurology
2nd Jul 202110:41 amRNSElliott Advisors (UK) letter to GSK
1st Jul 20212:29 pmRNSTotal Voting Rights
25th Jun 20214:54 pmRNSDirector/PDMR Shareholding
24th Jun 202111:07 amRNSDirector/PDMR Shareholding
23rd Jun 202111:00 amRNSGSK to deliver step-change in growth & performance
22nd Jun 20217:00 amRNSViiV/Halozyme sign exclusive licensing agreement
14th Jun 202111:58 amRNSGSK and iTeos announce collaboration for EOS-448
11th Jun 20214:54 pmRNSDirector/PDMR Shareholding
9th Jun 20213:28 pmRNSDirector/PDMR Shareholding
4th Jun 20214:02 pmRNSGSK recommend ADR holders reject mini-tender offer
1st Jun 202111:33 amRNSTotal Voting Rights
27th May 20219:21 amRNSDirector/PDMR Shareholding
27th May 20217:00 amRNSSanofi and GSK initiate new Phase 3 clinical study
27th May 20217:00 amRNSGSK/Vir Sotrovimab FDA Emergency Use Authorization
24th May 202110:10 amRNSDirector/PDMR Shareholding
21st May 202112:58 pmRNSGSK/VIR sotrovimab receives positive EMA opinion
18th May 20211:52 pmRNSBlock listing Interim Review
18th May 20217:00 amRNSMedicago/GSK COVID-19 Vaccine Positive Ph2 Results
17th May 20217:00 amRNSSanofi/GSK COVID-19 Vaccine Positive Ph2 Results
13th May 20214:46 pmRNSDirector/PDMR Shareholding
11th May 202112:54 pmRNSDirector/PDMR Shareholding
11th May 202111:30 amRNSEMTN Prospectus
6th May 20215:50 pmRNSBoard and Committee Changes
5th May 20216:23 pmRNSResult of AGM
4th May 20214:29 pmRNSTotal Voting Rights
28th Apr 20215:33 pmRNSDirector/PDMR Shareholding
28th Apr 202112:00 pmRNS1st Quarter Results
26th Apr 20214:14 pmRNSDirector/PDMR Shareholding
23rd Apr 20213:00 pmRNSEU approves GSK’s JEMPERLI (dostarlimab-gxly)
23rd Apr 20217:00 amRNSFDA approves GSK’s JEMPERLI (dostarlimab-gxly)
16th Apr 20214:00 pmRNSDirector/PDMR Shareholding
15th Apr 20213:21 pmRNSDirector/PDMR Shareholding
15th Apr 202110:17 amRNSDirector/PDMR Shareholding
14th Apr 20212:14 pmRNSDirector/PDMR Shareholding
14th Apr 202111:58 amRNSDirector/PDMR Shareholding
12th Apr 20215:32 pmRNSDirector/PDMR Shareholding
12th Apr 20219:48 amRNSDirector/PDMR Shareholding
9th Apr 20215:34 pmRNSDirector/PDMR Shareholding
9th Apr 20211:35 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.